ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Analysts

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have been given an average recommendation of “Moderate Buy” by the six ratings firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $4.60.

A number of research firms have recently issued reports on ALXO. Wall Street Zen raised shares of ALX Oncology from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Weiss Ratings downgraded shares of ALX Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 5th.

ALX Oncology Stock Performance

Shares of NASDAQ:ALXO opened at $2.06 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 9.71 and a quick ratio of 9.71. ALX Oncology has a 1 year low of $0.80 and a 1 year high of $2.66. The firm has a market capitalization of $284.86 million, a PE ratio of -1.82 and a beta of 0.42. The business’s 50 day moving average price is $1.94 and its 200-day moving average price is $1.97.

ALX Oncology (NASDAQ:ALXO) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.01. As a group, equities research analysts expect that ALX Oncology will post -0.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. State Street Corp boosted its holdings in shares of ALX Oncology by 11.0% during the 4th quarter. State Street Corp now owns 124,228 shares of the company’s stock worth $140,000 after purchasing an additional 12,300 shares during the last quarter. Beacon Pointe Advisors LLC acquired a new stake in shares of ALX Oncology in the second quarter valued at approximately $26,000. Callan Family Office LLC purchased a new position in ALX Oncology during the second quarter worth approximately $46,000. The Manufacturers Life Insurance Company purchased a new position in ALX Oncology during the second quarter worth approximately $64,000. Finally, Bridgeway Capital Management LLC acquired a new position in ALX Oncology during the third quarter worth $66,000. 97.97% of the stock is owned by hedge funds and other institutional investors.

About ALX Oncology

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.